Company intelligence / Profile preview

BiologyWorks

Los Angeles, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

BiologyWorks’ k(now)™ handheld molecular test has demonstrated 99.1% accuracy compared to RT-PCR for COVID‑19. The platform is CE-marked and available for point-of-care use in Europe and other regions outside the US. Clinical trials confirm high reliability and rapid results within 45 minutes

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic test (Handheld molecular testing device)
Industry: Molecular Diagnostics

Partnerships

Alfred Mann Foundation (originated research/patents)Bill & Melinda Gates Foundation (grant support)

Beyond the preview

Go deeper on BiologyWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiologyWorks.

Explore the full profile